Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection."

NCT03502005 is registered in ClinicalTrials.gov with Midland Research Group, Inc. as lead sponsor.

NCT NCT03502005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection."
Lead sponsor
Midland Research Group, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2018
Completion date
December 30, 2019
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus